{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:49:19Z","timestamp":1791503359540,"version":"4.3.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":92,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","award":["R325-A18705"],"award-info":[{"award-number":["R325-A18705"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1U01CA257679-01A1"],"award-info":[{"award-number":["1U01CA257679-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Multiple myeloma (MM) accounts for approximately 1% of incident cancers worldwide and carries substantial mortality. Diagnostic delay is common, with more than one-third of patients requiring emergency care at diagnosis, a presentation linked to inferior prognosis. Pain is a frequent early MM symptom, yet the extent and prognostic relevance of prediagnostic opioid use remains poorly characterized. Using nationwide Danish registers, we conducted a matched case-control analysis of prediagnostic opioid use, irrespective of indication, and its association with overall survival (OS) among MM patients. The study included 6,953 MM patients diagnosed in 2001\u20132021 and 101,793 matched population controls. Compared with controls, opioid use was first elevated among MM cases approximately 2.25 years before diagnosis, increasing more consistently closer to diagnosis. High prediagnostic opioid use (\u2265\u200910\u00a0mg daily oral morphine equivalents) was associated with shorter OS, compared with no opioid use (1-year OS 72% vs. 82%; adjusted hazard ratio 1.23, 95% CI 1.07\u20131.41). These findings indicate that opioid use increases closer to MM diagnosis date, likely reflecting pain related to undiagnosed MM. Furthermore, prediagnostic opioid use was associated with shorter OS independently of available prognostic factors, including ISS stage and myeloma bone disease.<\/jats:p>","DOI":"10.1038\/s41598-026-59999-2","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:46:06Z","timestamp":1783604766000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prediagnostic opioid use and survival in multiple myeloma: a nationwide register-based study"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3138-4591","authenticated-orcid":false,"given":"Jojo","family":"Biel-Nielsen Dietz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragnar P\u00e9tur","family":"Kristj\u00e1nsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d3lafur Birgir","family":"Dav\u00eddsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Rostgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tereza Fait","family":"Kadlec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emelie Curovic","family":"Rotbain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Signe Holst","family":"S\u00f8egaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigr\u00fan","family":"Thorsteinsd\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agoston Gyula","family":"Szabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten Utoft","family":"Niemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Hjalgrim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Brieghel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"59999_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"59999_CR2","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","volume":"113","author":"O Landgren","year":"2009","unstructured":"Landgren, O. et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: A prospective study. Blood 113, 5412\u20135417 (2009).","journal-title":"Blood"},{"key":"59999_CR3","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1056\/NEJMoa070389","volume":"356","author":"RA Kyle","year":"2007","unstructured":"Kyle, R. A. et al. Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma. N Engl. J. Med. 356, 2582\u20132590 (2007).","journal-title":"N Engl. J. Med."},{"key":"59999_CR4","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1182\/blood-2010-04-282848","volume":"116","author":"SY Kristinsson","year":"2010","unstructured":"Kristinsson, S. Y. et al. Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: A population-based study. Blood 116, 2651\u20132655 (2010).","journal-title":"Blood"},{"key":"59999_CR5","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1001\/jamaoncol.2015.23","volume":"1","author":"EE Sigurdardottir","year":"2015","unstructured":"Sigurdardottir, E. E. et al. The role of diagnosis and clinical follow-up of monoclonal gammopathy of undetermined significance on survival in multiple myeloma. JAMA Oncol. 1, 168\u2013174 (2015).","journal-title":"JAMA Oncol."},{"key":"59999_CR6","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1093\/qjmed\/hcm077","volume":"100","author":"CC Kariyawasan","year":"2007","unstructured":"Kariyawasan, C. C., Hughes, D. A., Jayatillake, M. M. & Mehta, A. B. Multiple myeloma: Causes and consequences of delay in diagnosis. QJM 100, 635\u2013640 (2007).","journal-title":"QJM"},{"key":"59999_CR7","doi-asserted-by":"crossref","unstructured":"Lyratzopoulos, G., Wardle, J. & Rubin, G. Rethinking diagnostic delay in cancer: How difficult is the diagnosis? BMJ (Online) 349 (2014).","DOI":"10.1136\/bmj.g7400"},{"key":"59999_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/2052-1839-13-9","volume":"13","author":"DA Howell","year":"2013","unstructured":"Howell, D. A. et al. Time-to-diagnosis and symptoms of myeloma, lymphomas and leukaemias: a report from the Haematological Malignancy Research Network. BMC Blood Disord. 13, 9 (2013).","journal-title":"BMC Blood Disord"},{"key":"59999_CR9","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.3399\/bjgp15X683545","volume":"65","author":"EA Shephard","year":"2015","unstructured":"Shephard, E. A. et al. Quantifying the risk of multiple myeloma from symptoms reported in primary care patients: A large case-control study using electronic records. Br. J. Gen. Pract. 65, e106\u2013e113 (2015).","journal-title":"Br. J. Gen. Pract."},{"key":"59999_CR10","doi-asserted-by":"publisher","first-page":"702","DOI":"10.3122\/jabfm.2016.06.150393","volume":"29","author":"N Goldschmidt","year":"2016","unstructured":"Goldschmidt, N., Zamir, L., Poperno, A., Kahan, N. R. & Paltiel, O. Presenting signs of multiple myeloma and the effect of diagnostic delay on the prognosis. J. Am. Board Fam. Med. 29, 702\u2013709 (2016).","journal-title":"J. Am. Board Fam. Med."},{"key":"59999_CR11","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1038\/bjc.2012.408","volume":"107","author":"L Elliss-Brookes","year":"2012","unstructured":"Elliss-Brookes, L. et al. Routes to diagnosis for cancer - Determining the patient journey using multiple routine data sets. Br. J. Cancer. 107, 1220\u20131226 (2012).","journal-title":"Br. J. Cancer"},{"key":"59999_CR12","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar, S. K. et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 111, 2516\u20132520 (2008).","journal-title":"Blood"},{"key":"59999_CR13","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar, S. V. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am. J. Hematol. 97, 1086\u20131107 (2022).","journal-title":"Am. J. Hematol."},{"key":"59999_CR14","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3816\/CLML.2010.n.080","volume":"10","author":"G Talamo","year":"2010","unstructured":"Talamo, G. et al. Beyond the CRAB Symptoms: A study of presenting clinical manifestations of multiple myeloma. Clin. Lymphoma Myeloma Leuk. 10, 464\u2013468 (2010).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"59999_CR15","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/leu.2010.62","volume":"24","author":"E Terpos","year":"2010","unstructured":"Terpos, E., Berenson, J., Cook, R. J., Lipton, A. & Coleman, R. E. Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease. Leukemia 24, 1043\u20131049 (2010).","journal-title":"Leukemia"},{"key":"59999_CR16","doi-asserted-by":"publisher","first-page":"685","DOI":"10.4065\/84.8.685","volume":"84","author":"JP Bida","year":"2009","unstructured":"Bida, J. P. et al. Disease Associations With Monoclonal Gammopathy of Undetermined Significance: A Population-Based Study of 17,398 Patients. Mayo Clin. Proc. 84, 685\u2013693 (2009).","journal-title":"Mayo Clin. Proc."},{"key":"59999_CR17","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/j.1365-2141.2006.06217.x","volume":"134","author":"J Pepe","year":"2006","unstructured":"Pepe, J. et al. Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of undetermined significance. Br. J. Haematol. 134, 485\u2013490 (2006).","journal-title":"Br. J. Haematol."},{"key":"59999_CR18","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1359\/JBMR.041131","volume":"20","author":"LJ Melton","year":"2005","unstructured":"Melton, L. J., Kyle, R. A., Achenbach, S. J., Oberg, A. L. & Rajkumar, S. V. Fracture risk with multiple myeloma: A population-based study. J. Bone Miner. Res. 20, 487\u2013493 (2005).","journal-title":"J. Bone Miner. Res."},{"key":"59999_CR19","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1365-2141.2006.06269.x","volume":"135","author":"H Gregersen","year":"2006","unstructured":"Gregersen, H. et al. Fracture risk in patients with monoclonal gammopathy of undetermined significance. Br. J. Haematol. 135, 62\u201367 (2006).","journal-title":"Br. J. Haematol."},{"key":"59999_CR20","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jpainsymman.2024.06.006","volume":"68","author":"B Daniels","year":"2024","unstructured":"Daniels, B. et al. Trajectories of Opioid Use Before and After Cancer Diagnosis: A Population-Based Cohort Study. J. Pain Symptom Manage. 68, 282\u2013291e11 (2024).","journal-title":"J. Pain Symptom Manage."},{"key":"59999_CR21","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar, S. K. et al. Continued improvement in survival in multiple myeloma: Changes in early mortality and outcomes in older patients. Leukemia 28, 1122\u20131128 (2014).","journal-title":"Leukemia"},{"key":"59999_CR22","doi-asserted-by":"crossref","unstructured":"Parrondo, R. D., Ailawadhi, S. & Cerchione, C. Bispecific antibodies for the treatment of relapsed\/refractory multiple myeloma: updates and future perspectives. Front Oncol 14 (2024).","DOI":"10.3389\/fonc.2024.1394048"},{"key":"59999_CR23","doi-asserted-by":"crossref","unstructured":"Miller, K., Hashmi, H. & Rajeeve, S. Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma. Front Oncol 14 (2024).","DOI":"10.3389\/fonc.2024.1398902"},{"key":"59999_CR24","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1056\/NEJMoa2409029","volume":"392","author":"MA Dimopoulos","year":"2025","unstructured":"Dimopoulos, M. A. et al. Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma. N. Engl. J. Med. 392, 1777\u20131788 (2025).","journal-title":"N. Engl. J. Med."},{"key":"59999_CR25","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1001\/jama.1992.03490060092030","volume":"268","author":"RA Deyo","year":"1992","unstructured":"Deyo, R. A., Rainville, J. & Kent, D. L. What can the history and physical examination tell us about low back pain? JAMA 268, 760\u2013765 (1992).","journal-title":"JAMA"},{"key":"59999_CR26","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S1470-2045(12)70041-4","volume":"13","author":"G Lyratzopoulos","year":"2012","unstructured":"Lyratzopoulos, G., Neal, R. D., Barbiere, J. M., Rubin, G. P. & Abel, G. A. Variation in number of general practitioner consultations before hospital referral for cancer: findings from the 2010 National Cancer Patient Experience Survey in England. Lancet Oncol. 13, 353\u2013365 (2012).","journal-title":"Lancet Oncol."},{"key":"59999_CR27","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1038\/s41375-020-0918-6","volume":"34","author":"G Cook","year":"2020","unstructured":"Cook, G., Larocca, A., Facon, T., Zweegman, S. & Engelhardt, M. Defining the vulnerable patient with myeloma\u2014a frailty position paper of the European Myeloma Network. Leukemia 34, 2285\u20132294 (2020).","journal-title":"Leukemia"},{"key":"59999_CR28","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s40266-012-0046-8","volume":"30","author":"MPH Koponen","year":"2013","unstructured":"Koponen, M. P. H. et al. Analgesic use and frailty among community-dwelling older people: A population-based study. Drugs Aging. 30, 129\u2013136 (2013).","journal-title":"Drugs Aging"},{"key":"59999_CR29","doi-asserted-by":"crossref","unstructured":"Murugappan, M. N. et al. Patient-reported frailty phenotype (PRFP) vs. International Myeloma Working Group frailty index (IMWG FI) proxy: A comparison between two approaches to measuring frailty. J Geriatr. Oncol 15 (2024).","DOI":"10.1016\/j.jgo.2023.101681"},{"key":"59999_CR30","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo, A. et al. Revised international staging system for multiple myeloma: A report from international myeloma working group. J. Clin. Oncol. 33, 2863\u20132869 (2015).","journal-title":"J. Clin. Oncol."},{"key":"59999_CR31","doi-asserted-by":"crossref","unstructured":"D\u2019Agostino, M. et al. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. J Clin. Oncol 40 (2022).","DOI":"10.1200\/JCO.22.02228"},{"key":"59999_CR32","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1177\/1403494810393562","volume":"39","author":"ML Gjerstorff","year":"2011","unstructured":"Gjerstorff, M. L. The Danish cancer registry. Scand. J. Public. Health. 39, 42\u201345 (2011).","journal-title":"Scand. J. Public. Health"},{"key":"59999_CR33","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1177\/1403494810387965","volume":"39","author":"CB Pedersen","year":"2011","unstructured":"Pedersen, C. B. The Danish Civil Registration System. Scand. J. Public. Health. 39, 22\u201325 (2011).","journal-title":"Scand. J. Public. Health"},{"key":"59999_CR34","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10654-014-9930-3","volume":"29","author":"M Schmidt","year":"2014","unstructured":"Schmidt, M., Pedersen, L. & S\u00f8rensen, H. T. The Danish Civil Registration System as a tool in epidemiology. Eur. J. Epidemiol. 29, 541\u2013549 (2014).","journal-title":"Eur. J. Epidemiol."},{"key":"59999_CR35","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/1403494810394717","volume":"39","author":"H Wallach Kildemoes","year":"2011","unstructured":"Wallach Kildemoes, H., Toft S\u00f8rensen, H. & Hallas, J. The Danish national prescription registry. Scand. J. Public. Health. 39, 38\u201341 (2011).","journal-title":"Scand. J. Public. Health"},{"key":"59999_CR36","doi-asserted-by":"publisher","first-page":"583","DOI":"10.2147\/CLEP.S99463","volume":"8","author":"P Gimsing","year":"2016","unstructured":"Gimsing, P. et al. The Danish National Multiple Myeloma Registry. Clin. Epidemiol. 8, 583\u2013587 (2016).","journal-title":"Clin. Epidemiol."},{"key":"59999_CR37","unstructured":"Rothman, K. J., Greenland, S. & Lash, T. L. Modern Epidemiology Vol. 1 (Wolters Kluwer Health\/Lippincott Williams & Wilkins, 2008)."},{"key":"59999_CR38","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp, P. R. et al. International staging system for multiple myeloma. J. Clin. Oncol. 23, 3412\u20133420 (2005).","journal-title":"J. Clin. Oncol."},{"key":"59999_CR39","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/pds.3945","volume":"25","author":"S Nielsen","year":"2016","unstructured":"Nielsen, S., Degenhardt, L., Hoban, B. & Gisev, N. A synthesis of oral morphine equivalents (OME) for opioid utilisation studies. Pharmacoepidemiol Drug Saf. 25, 733\u2013737 (2016).","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"59999_CR40","unstructured":"U.S. Dept. of Health Human Services. Opioid Oral Morphine Milligram Equivalent (MME) Conversion Factors table for prescription drug coverage. https:\/\/www.hhs.gov\/guidance\/sites\/default\/files\/hhs-guidance-documents\/Opioid%20Morphine%20EQ%20Conversion%20Factors%20%28vFeb%202018%29.pdf (2020)."},{"key":"59999_CR41","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.R-project.org\/ (2022)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59999-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59999-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59999-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:01:47Z","timestamp":1791500507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59999-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["59999"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-59999-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"12 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.B. received travel grants from AbbVie and AstraZeneca outside this study. E.C.R. received consultancy fees and\/or travel grants from AbbVie, Janssen, and AstraZeneca outside of this work.\u00a0A.G.S. has received research funding from GSK, BMS, Takeda, J&J, and consultancy fees from: GSK, Takeda, Sanofi and J&J.\u00a0E.H.R. has received consultancy fees and\/or travel grants from Abbvie, Janssen, and AstraZeneca outside this work.\u00a0C.U.N. received research funding and\/or consultancy fees from AstraZeneca, Johnson & Johnson, AbbVie, BeOne Medicines, Genmab, CSL Behring, Octapharma, Takeda, Eli Lily, Merck Sharp & Dohme, and the Novo Nordisk Foundation. All other authors declare no competing interests to disclose.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"31570"}}